Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.56 |
| ▸ | CMA1 | P23946 | 2/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746650 | 1.00 | AHR (0.56) | AHRCMA1EIF2AK2CRBNPDK2 | |
| SCHEMBL17080910 | 0.86 | AHR (0.53) | AHRCMA1EIF2AK2CRBNPDK2 | |
| SCHEMBL260278 | 0.86 | AHR (0.56) | AHRCMA1PDK2GAASMYD3 | |
| SCHEMBL2221081 | 0.84 | CA9 (0.57) | CRBNSMYD3MAOBCA9 | |
| SCHEMBL29754234 | 0.84 | CA9 (0.57) | CRBNSMYD3MAOBCA9 | |
| SCHEMBL24570314 | 0.82 | AHR (0.61) | AHRCMA1EIF2AK2CRBNPDK2 | |
| SCHEMBL4509576 | 0.82 | AHR (0.56) | AHRCMA1EIF2AK2CRBNPDK2 | |
| SCHEMBL29746444 | 0.82 | AHR (0.61) | AHRCMA1EIF2AK2CRBNPDK2 | |
| SCHEMBL290258 | 0.82 | AHR (0.61) | AHRCMA1EIF2AK2CRBNPDK2 | |
| SCHEMBL12123840 | 0.82 | AHR (0.56) | AHRCMA1EIF2AK2CRBNPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | ALIVEXIS, INC. (JP) | 2024-03-14 | — | — | US | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-20230293487-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| CN-116583286-A | Tetrahydrothienopyrimidine sulfonamide compounds | 某久拉斯株式会社 | 2023-08-11 | — | — | CN | disclosed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| CN-101679324-B | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2012-10-03 | — | — | CN | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| CN-101679324-A | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | AHR 1166/4885CMA1 30/4885EIF2AK2 2694/4885 |
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | TYMS, TYMP, TPMT | AHR 3341/4885CMA1 2774/4885EIF2AK2 1326/4885 |
| US-20230293487-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | RELA, NFKBIA, IKBKG | AHR 244/4885CMA1 2453/4885EIF2AK2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.